ReviewEuropean journal of medicinal chemistry2020
Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
Review in European journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Host-directed antiviral strategy targeting prohibitins: Mel56 suppresses influenza A virus and severe acute respiratory syndrome coronavirus 2 via modulation of antioxidant pathways and mitochondrial function.Microbiology spectrum · 2026Article
- Clarifying the active ingredients & pharmacological mechanisms of traditional Chinese medicines via modern pharmaceutical analysis techniques.Journal of pharmaceutical analysis · 2026Review
- Phloretin targeting the 3CLpro Cys144 exhibits broad-spectrum antiviral activity against swine enteric coronavirus.Virologica Sinica · 2026Article
- FL3 mitigates cardiac ischemia-reperfusion injury by promoting mitochondrial fusion to restore calcium homeostasis.Cell death discovery · 2025Article
- Emerging roles of prohibitins in cancer: an update.Cancer gene therapy · 2025Review
- Natural 7,8-secolignans fromJournal of traditional and complementary medicine · 2024Article
- Article
- Broad anti-pathogen potential of DEAD box RNA helicase eIF4A-targeting rocaglates.Scientific reports · 2023Article
- eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers.Frontiers in molecular biosciences · 2023Review
- The flavagline FL3 interferes with the association of Annexin A2 with the eIF4F initiation complex and transiently stimulates the translation ofFrontiers in cell and developmental biology · 2023Article
- Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?Engineering (Beijing, China) · 2022Review
- Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19.European journal of medicinal chemistry reports · 2022Review
- Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.Antiviral research · 2022Article
- The Impact of COVID-19 Pandemic on Seafood Safety and Human Health.Frontiers in microbiology · 2022Review
- Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain.Journal of molecular structure · 2021Article
- Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.Planta medica · 2021Review
- Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.Chemico-biological interactions · 2021Article
- A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavaglines are cyclopenta[b]benzofurans found in plants of the genus Aglaia, several species of which are used in traditional Chinese medicine. These compounds target the initiation factor of translation eIF4A and the scaffold proteins prohibitins-1 and 2 (PHB1/2) to exert various pharmacological activities, including antiviral effects against several types of viruses, including coronaviruses. This review is focused on the antiviral effects of flavaglines and their therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.